A Revolutionary Approach to Cancer Treatment

Jounce Therapeutics, Inc. (NASDAQ: JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in the Phase 2 portion of the Phase 1/2 ICONIC trial.

Year Invested: 2013
Location: Cambridge, Mass.
Visit: www.jouncetx.com

Recent News

April 12, 2018
Jounce Therapeutics to Present Nonclinical Translational Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting

March 8, 2018
Jounce Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

March 5, 2018
Jounce Therapeutics to Present at Cowen and Company 38th Annual Health Care Conference

Read More News

Associated Team Members

Robert Tepper, M.D.

Cary Pfeffer, M.D.

Robert Kamen, Ph.D.
Venture Partner